The Global Health Body Raises Alert Over Acute Shortage of Weight-Loss Jabs
Fewer than 10% of individuals who could benefit from obesity jabs such as Wegovy are able to get them, caution the WHO as it releases its first recommendations on the drugs.
With in excess of 1,000,000,000 people worldwide currently obese, it is urging broader and more equitable access to GLP-1 medication.
Per projections, in excess of 2,000,000,000 will be obese by 2030 if no action is taken.
"Our latest guidelines recognises that excess weight is a long-term condition that can be addressed with comprehensive and lifelong care," stated its chief Tedros Adhanom Ghebreyesus.
Significant expense, insufficient output, and logistical bottlenecks are significant barriers to broad availability to the jabs that can help people shift substantial weight, says the agency.
Skinny Jab Scarcity
Despite the present best projected outlook, the production of such drugs might only reach approximately 100 million people – under 10% of eligible patients, per the health organization.
The recommendation urges governments and firms to widen access, through strategies including voluntary licensing.
Exclusive production rights on semaglutide – the main ingredient of a leading brand – is due to expire in a number of nations in 2026.
How Obesity Injections Work
GLP-1 drugs imitate a biological compound to slow digestion, curb appetite and boost feelings of fullness so people reduce food intake.
Patients typically begin shedding pounds in the initial weeks of starting on the regular doses.
Studies suggests people may put most of the weight back on after a year of discontinuing the drug, as their typical food cravings come back.
To be above a healthy weight raises your chance for developing health problems, including diabetes, heart disease, brain attack, and specific cancers.
Obesity impacts people in all nations and was responsible for 3.7 million fatalities worldwide in 2024, per the health agency.
